Rapid and simultaneous tuberculosis and antibiotic susceptibility testing for the diagnosis of and rifampicin resistance a review of diagnostic accuracy
This report is an upgrade from a CADTH report (Summary of Abstracts) published in June 2020. The aim of this current report is to review the evidence regarding the rapid and simultaneous tuberculosis and antibiotic susceptibility testing for PTB and rifampicin resistance. This report will be followe...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
Canadian Agency for Drugs and Technologies in Health
2020, December 10, 2020
|
| Edition: | Version: 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | This report is an upgrade from a CADTH report (Summary of Abstracts) published in June 2020. The aim of this current report is to review the evidence regarding the rapid and simultaneous tuberculosis and antibiotic susceptibility testing for PTB and rifampicin resistance. This report will be followed by a second report on the cost-effectiveness rapid and simultaneous tuberculosis and antibiotic susceptibility testing for the diagnosis of pulmonary tuberculosis and rifampicin resistance. Additionally, these reports are components of a larger CADTH Condition Level Review on tuberculosis. A condition level review is an assessment that incorporates all aspects of a condition, from prevention, detection, treatment, and management |
|---|---|
| Physical Description: | 1 PDF file (30 pages) illustration |